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Excitotoxicity mediated by glutamate receptors
plays crucial roles in ischemia and other neuro-
degenerative diseases. Whereas overactiva-
tion of ionotropic glutamate receptors is neuro-
toxic, the role of metabotropic glutamate
receptors (mGluRs), and especially mGluR1,
remains equivocal. Here we report that activa-
tion of NMDA receptors results in calpain-medi-
ated truncation of the C-terminal domain of
mGluR1a at Ser936. The truncated mGluR1a
maintains its ability to increase cytosolic cal-
cium while it no longer activates the neuropro-
tective PI3K-Akt signaling pathways. Full-length
and truncated forms of mGluR1a play distinct
roles in excitotoxic neuronal degeneration in
cultured neurons. A fusion peptide derived
from the calpain cleavage site of mGluR1a effi-
ciently blocks NMDA-induced truncation of
mGluR1a in primary neuronal cultures and
exhibits neuroprotection against excitotoxicity
both in vitro and in vivo. These findings shed
light on the relationship between NMDA and
mGluR1a and indicate the existence of a
positive feedback regulation in excitotoxicity
involving calpain and mGluR1a.
INTRODUCTION
Glutamate is the major excitatory neurotransmitter in the
brain. Receptors for glutamate consist of three types of
ionotropic receptors, namely NMDA, AMPA, and kainate
receptors, and three groups of metabotropic receptors.
In addition to their physiological roles in normal neuro-
transmission, glutamate receptors play critical roles in
neuronal death resulting from ischemia and other neuro-
degenerative diseases. Ionotropic glutamate receptors,
especially NMDA receptors, have been repeatedly shown
to contribute to excitotoxicity. However, the roles of
metabotropic glutamate receptors, especially of group I
metabotropic glutamate receptors (mGluRI, includingNmGluR1 and mGluR5), in excitotoxicity remain contro-
versial.
Activation of group I mGluRs appears to be neuropro-
tective under various conditions. The agonist of group I
mGluRs, DHPG, prevented nitric oxide-, hydrogen perox-
ide-, or platelet-activating factor-induced neurotoxicity in
neuronal cultures (Vincent and Maiese, 2000; Zhu et al.,
2004). Activation of mGluRs also protected neurons from
oxidative stress (Sagara and Schubert, 1998). In organo-
typic hippocampal slice cultures, mGluR1 activation pro-
tected against NMDA-induced excitotoxicity (Blaabjerg
et al., 2003). Selective mGluRI blockade exacerbated Aß
toxicity (Allen et al., 1999). Recent studies indicated that
the neuroprotective effects of mGluRI were mediated by
activation of PI3K-Akt signaling through the formation
of an mGluRI-Homer-PIKE-L signaling complex (Rong
et al., 2003). Activation of Akt and neuroprotection by
mGluRI were also reported in other studies (Hou and
Klann, 2004; Chong et al., 2006).
Numerous experiments demonstrate neurotoxic effects
of mGluRI activation, however. In models of cerebral is-
chemia, activation of mGluRI, especially of mGluR1, is
neurotoxic, while antagonists of mGluR1 are neuroprotec-
tive. The neurotoxic effects of mGluR1 activity in ischemia
might be due to their effects on cytosolic free Ca2+
and their stimulation of glutamate release (Pellegrini-
Giampietro, 2003).
Because multiple types of glutamate receptors are si-
multaneously activated under excitotoxic conditions, in-
teractions between receptors might play important roles
in determining the outcome of toxic insults. The present
study was therefore directed at evaluating interactions
between NMDA and mGluR1a receptors. Our results indi-
cate that overactivation of NMDA receptors alters signal-
ing mechanisms and roles in excitotoxicity of mGluR1a
through calpain-mediated truncation.
RESULTS
NMDA Receptor Activation Induces C-Terminal
Truncation of mGluR1a
To detect possible mGluR1a modifications following glu-
tamate-induced excitotoxicity, cultured cortical neurons
(14–18 days in vitro; DIV) were incubated with glutamate
(100 mM) for 1–60 min. Total cell lysate was collectedeuron 53, 399–412, February 1, 2007 ª2007 Elsevier Inc. 399
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Truncation of mGluR1a as a Result of
NMDA Receptor Activation
(A) Neurons were treated with glutamate for the
indicated periods of time. Total cell lysates
were blotted with an antibody against the
C terminus of mGluR1a (mGluR1a1142–1160).
(B) Neurons were transfected with myc-
mGluR1a and treated with glutamate. Total
cell lysates were probed with anti-myc anti-
body (the schematic shows locations of
epitopes; the arrow indicates the putative
cleavage site).
(C) Neurons were treated with glutamate and
whole lysates were blotted with antibodies
against mGluR5, GluR2/3, and VGluT1.
(D and F) Representative blot and quantifica-
tion of the effects of an NMDA receptor antag-
onist on glutamate-induced truncation of
mGluR1a. Neurons were treated with gluta-
mate alone (n = 7) or glutamate + MK 801
(n = 4), DNQX (n = 5), LY367385 (n = 4), or
MPEP (n = 4). Total cell lysates were blotted
with anti-mGluR1a1142–1160.
(E and F) NMDA induced a similar truncation of
mGluR1a. Neurons were treated with gluta-
mate or NMDA (n = 5) and whole lysates were blotted with anti-mGluR1a1142–1160. Results are means ± SEM. *p < 0.001, Student’s t test.
(G and H) Concentration and time dependency of NMDA-induced truncation of mGluR1a. Cortical neurons were treated for 1 hr with the
indicated concentrations of NMDA (G) or were treated with 10 mM NMDA for the indicated periods of time (H). Results are means ± SEM of four
experiments.immediately after treatment and subjected to SDS-PAGE
and immunoblotting with an antibody against the carboxyl
terminus (residues 1142–1160) of mGluR1a (Figure 1A).
Levels of full-length mGluR1a decreased with increasing
incubation time, while levels of a low-molecular weight
band at about 38 kDa increased, suggesting that trunca-
tion of mGluR1a occurred at the C terminus. To probe
the amino terminus of mGluR1a after truncation, cortical
neurons were transfected with an mGluR1a construct
tagged with a myc epitope at the N terminus (myc-
mGluR1a, the EQKLISEEDL epitope, was inserted in-
frame after Ala30 of mGluR1a; Francesconi and Duvoisin,
2002) after 3 days in vitro. Neurons were transfected
with a calcium phosphate precipitation method modified
for high transfection rate (Jiang et al., 2004). One week
later, transfected neurons were treated with 100 mMgluta-
mate for 1 hr and total lysates were processed for western
blots. When probed with an anti-myc antibody, blots re-
vealed a low-molecular weight band at about 100 kDa
after glutamate treatment (Figure 1B), which corresponds
to the N-terminal fragment after truncation. The optical
density of the original myc-mGluR1a did not decrease sig-
nificantly, suggesting that only a small fraction of overex-
pressed myc-mGluR1a was cleaved. Because the appar-
ent molecular weight of mGluR1a on SDS-PAGE is about
140 kDa, our data suggested that glutamate induced
truncation of mGluR1a in the C terminus, most likely at
a single cleavage site.
To test for the specificity of glutamate-mediated trunca-
tion of mGluR1a, immunoblots were also probed with an
antibody against mGluR5, another member of group I400 Neuron 53, 399–412, February 1, 2007 ª2007 Elsevier Inc.mGluRs, which shares a high similarity with mGluR1a.
As shown in Figure 1C, levels of mGluR5 were not sig-
nificantly altered by glutamate. Similarly, no significant
changesoccurred to theGluR2/3 subunits ofAMPA recep-
tors, or to the vesicular glutamate transporter (VGluT1),
a presynaptic protein in glutamatergic synapses.
Selective glutamate receptor antagonists were used to
identify the glutamate receptor(s) involved in mGluR1a
truncation. Glutamate (100 mM, 1 hr) induced a significant
reduction in the levels of mGluR1a. An NMDA receptor an-
tagonist, MK-801 (10 mM), completely blocked this effect,
whereas the non-NMDA glutamate receptor antagonist,
DNQX (100 mM), had no effect. Similarly, mGluR1 block-
ade with LY367385 (100 mM) or mGluR5 blockade with
MPEP (100 mM) did not prevent truncation (Figures 1D
and 1F). Furthermore, when cortical neurons were treated
with NMDA (50 mM, 1 hr), a similar degree of mGluR1a
truncation was produced (Figure 1E). To characterize
NMDA-induced mGluR1a truncation, concentration and
time dependencies of NMDA effects were studied. Corti-
cal neurons were first incubated with 1–100 mM NMDA
for a fixed period of time (1 hr) (Figure 2G). The minimum
concentration of NMDA required to induce significant
mGluR1a truncation was 10 mM (p < 0.001, n = 4, Stu-
dent’s t test for control versus 10 mM). In a following exper-
iment, cortical neurons were incubated with 10 mMNMDA
for 1–60 min (Figure 2H). The minimum time required for
10 mM NMDA to induce truncation was 5 min (p < 0.01,
n = 4, Student’s t test for control versus 5 min). In sum-
mary, these data indicate that activation of NMDA recep-
tors but not non-NMDA glutamate receptors results in
Neuron
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Calpain at Ser936
(A) NMDA-induced truncation of mGluR1a was
significantly blocked by calpain inhibitor III
(Calpi3) but not by caspase inhibitor cpm-
VAD-CHO (Caspi).
(B) Calpain was activated by NMDA. Neurons
were treated as indicated and total cell ly-
sates were blotted with anti-spectrin or anti-
mGluR1a1142–1160, respectively. Only the deg-
radation bands of spectrin (spectrin DB, at
145 kD) are shown. NMDA-induced spectrin
degradation and mGluR1a truncation were
blocked by ifenprodil but not by NVP-AAM077.
(C) Immunoprecipitated myc-mGluR1a was di-
gested with m-calpain at the indicated concen-
trations (U/ml) for 30min. The digestedmaterial
was processed for SDS-PAGE and subjected
to silver staining or immunoblots. With silver
staining, myc-mGluR1a (140 kDa) was
cleaved by calpain into two bands of molecular
weight 100 kDa (corresponding to the N-termi-
nal fragment, as it was detected with the anti-
myc antibody) and 38 kDa (corresponding to
the C-terminal fragment, as it was detected
with anti-mGluR1a1142–1160).
(D) Alignment of mGluR1 (residues 902–941)
and mGluR5 (residues 889–927) sequences
surrounding the calpain cleavage site and
sequence of the TAT-mGluR1 peptide. The
calpain cleavage site was identified by sequen-
cing calpain-digested GST-mGluR1889–1058
fusion protein. The TAT-mGluR1 peptide was
designed to generate a cell-permeable (by TAT
PTD sequence) peptide that contains a se-
quence that overlaps the calpain cutting site in
mGluR1a.
(E) Immunoblot probed with anti-myc antibody showing that myc-mGluR1aS936D exhibited the same molecular weight as the N-terminal fragment of
calpain-cleaved myc-mGluR1a. Lane 1 shows myc-mGluR1a immunoprecipitated from HEK293 cells, lanes 2 and 3 show myc-mGluR1a digested
with increasing calpain concentrations, and lane 4 shows myc-mGluR1aS936D.
(F) TAT-mGluR1 peptide blocked NMDA-induced mGluR1a truncation. Neurons were pretreated with the TAT-mGluR1 peptide or vehicle followed by
NMDA, and total cell lysates were blotted with anti-mGluR1a1142–1160 or anti-spectrin antibodies.mGluR1a truncation and that mGluR1a truncation re-
quires prolonged activation of NMDA receptors.
mGluR1a Is Truncated by Calpain at Ser936
We then determined which protease(s) mediated NMDA-
induced mGluR1a truncation. Previous studies have indi-
cated that both the calcium-dependent neutral protease
calpain and caspases could be activated by neurotoxic
concentrations of NMDA. Cortical neurons were pre-
treated with a calpain inhibitor, the cell-permeable calpain
inhibitor III (10 mM), or the caspase inhibitor cpm-VAD-
CHO for 2 hr followed by 50 mM NMDA for 1 hr. Pretreat-
ment with calpain inhibitor III significantly blocked NMDA-
induced truncation (Figure 2A), while cpm-VAD-CHO had
no effect. To confirm the activation of calpain by NMDA
under our experimental conditions, we determined the
levels of spectrin degradation fragments. The 145 kDa
spectrin degradation band (spectrin DB), which is widely
used as a marker of calpain activation, could not be de-
tected under control conditions but appeared after treat-Nment with NMDA (Figure 2B). In addition, NMDA-induced
spectrin degradation could be blocked by ifenprodil
(10 mM), a selective antagonist of NR2B subunit-containing
NMDAreceptors, butnotbyNVP-AAM077 (0.4mM),aselec-
tive antagonist for NR2A subunit-containing NMDA recep-
tors. Similarly, NMDA-induced mGluR1a truncation was
selectively blocked by ifenprodil but not by NVP-AAM077.
Note that under these conditions, the 120 kDa spectrin deg-
radation fragment generated by caspase-induced spectrin
truncation (Newcomb et al., 2000) was never observed, fur-
ther strengthening the conclusion that calpain but not cas-
pase was responsible for mGluR1a truncation.
The involvement of calpain in mGluR1a truncation did
not necessarily imply that calpain could directly cleave
the C terminus of mGluR1a. To confirm that mGluR1a
truncation is directly mediated by calpain, we first trans-
fected HEK293 cells with the N-terminal myc-epitope-
tagged mGluR1a. Two days later, mGluR1awas immuno-
precipitated with anti-mGluR1a C-terminal antibody and
incubated with different concentrations of m-calpain foreuron 53, 399–412, February 1, 2007 ª2007 Elsevier Inc. 401
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for SDS-PAGE and silver staining, and the rest of the sam-
pleswereused forwestern blotswith antibodiesagainst the
myc epitope or mGluR1a C terminus, respectively (Fig-
ure 2C). With silver staining, the density of the 145 kDa
band that represents full-length mGluR1a decreased
dose dependently with calpain treatment. In parallel, two
additional bands appeared after calpain treatment, with
apparent molecular weights of 100 kDa and 38 kDa, re-
spectively. The 100 kDa band proved to be the N terminus
of mGluR1a derived from truncation, as it reacted with the
anti-myc antibody. Likewise, the 38 kDa protein proved to
be the C terminus of mGluR1a, as it was labeled with
the anti-mGluR1a C-terminal antibody. These data indi-
cated that calpain could directly cleave mGluR1a at the
C terminus.
From the size of mGluR1a fragments after cleavage, we
deducted that the calpain cleavage site in mGluR1a
should be between residue I812 (the molecular weight of
the sequence from I812 to the C terminus is 38.25 kDa)
and S943 (the molecular weight from the N terminus to
Ser943 is 105.62 kDa). We therefore made a GST fusion
protein containing the sequence of mGluR1a from I812 to
S943. The GST fusion protein was expressed in and puri-
fied from BL21 Escherichia coli and digested with calpain.
This fusion protein became about 2 kDa smaller after
digestion, suggesting that the cleavage site was close to
S943. To get enough C-terminal fragment for Edman pro-
tein sequencing, another construct was made by fusing
the mGluR1a sequence from N889 to L1058 to the C termi-
nus of GST. As expected, after digestion with calpain, this
fusion protein generated a 10 kDa fragment. The N termi-
nus of this fragment was sequenced to be YQGS with
Edman degradation, indicating that the calpain cleavage
site in mGluR1a is between S936 and Y937 (Figure 2D).
The molecular weight (MW) of mGluR1a from residues
1–936 is 104.87 kDa, which matches well with the appar-
ent MW of the N-terminal fragment after truncation. The
MW of mGluR1a residues 937–1199 is 28.41 kDa, which
is lower than the 38 kDa apparent MW of the C-terminal
fragment. However, the C-terminal domain of mGluR1a
has a high percentage of proline (45 out of the 263 amino
acids), with some proline-rich domains composed solely
of prolines. Proline-rich proteins normally show higher
apparent MW on SDS-PAGE, which might explain the
seemingly different molecular weights of the C-terminal
fragment. To obtain further confirmation of this truncation
site, a stop codon was introduced into the myc-mGluR1a
plasmid immediately after Ser936 to generate a construct
for truncated mGluR1a (myc-mGluR1aS936D). Trans-
fected in HEK293 cells, this construct generated a protein
with the same apparent molecular weight (100 kDa)
as the mGluR1a N-terminal fragment generated after
calpain-mediated truncation (Figure 2E).
To selectively block calpain-mediated truncation of
mGluR1a, a peptide was constructed by fusing the
mGluR1a sequence spanning the calpain cleavage site
with the TAT protein transduction domain, a procedure402 Neuron 53, 399–412, February 1, 2007 ª2007 Elsevier Inc.that has been used to transfer material across cell mem-
branes (Wadia et al., 2004). We reasoned that this peptide
would compete with endogenous mGluR1a for calpain
and therefore protect it from truncation. Incubation of
brain membrane fractions with calpain resulted in trunca-
tion of both mGluR1a and spectrin. The TAT-mGluR1 fu-
sion peptide dose dependently reduced calpain-mediated
truncation of mGluR1a but not of spectrin. The TAT
peptide itself showed no significant effect on calpain-
mediated truncation of mGluR1a or spectrin (see Supple-
mental Data available with this article online). We then
tested the effect of the peptide on cultured neurons. Cor-
tical cultures were incubated with different concentrations
of TAT-mGluR1 for 90 min followed by 50 mM NMDA for
1 hr. As shown in Figure 2F, treatment with the peptide
resulted in a dose-dependent inhibition of NMDA-induced
mGluR1a truncation. At the lower concentrations (1–
2 mM), the peptide significantly reduced mGluR1a trunca-
tion with little effect on spectrin degradation, while at
higher concentrations (4–8 mM), spectrin degradation
was also blocked.
C-Terminal Truncated mGluR1a Remains Functional
The main signaling mechanism activated by mGluR1a
consists of PI hydrolysis through G protein and phospho-
lipase C, which eventually leads to calcium release from
internal calcium stores. Therefore, we first performed
calcium imaging to determine whether mGluR1a remains
functional following C-terminal truncation. Wild-type
mGluR1 (myc-mGluR1a) or the truncated form (myc-
mGluR1aS936D) was cotransfected with DsRED (red
fluorescent protein) into HEK293 cells. Two days after
transfection, cells were loaded with a calcium reporter,
Oregon green 488 BAPTA-1 AM (0.63% in extracellular
solution). As shown in Figure 3, a significant increase in in-
tracellular calcium concentration could be detected after
treatment of cells transfected with myc-mGluR1a with
100 mM DHPG, a selective agonist for group I mGluRs
(maximum DF/F = 30.6 ± 4.2%; n = 8). This calcium re-
sponse requires mGluR1a activation because no change
in fluorescent signals could be observed in nontransfected
cells. In cells transfected with myc-mGluR1aS936D, DHPG
could induce qualitatively similar, although significantly
smaller, calcium transients (maximum DF/F = 20.1 ±
2.1%; n = 10; p < 0.05, Student’s t test for myc-mGluR1a
versus myc-mGluR1aS936D). These data indicated that
mGluR1a remains functional following C-terminal trunca-
tion at Ser936.
C-Terminal Truncation Alters mGluR1a Signaling
Activation of mGluR1a can also stimulate nonselective
cation excitatory postsynaptic conductance.We therefore
analyzed mGluR1a-dependent currents before and after
calpain-mediated truncation. We transfected HEK293
cells with either myc-mGluR1a or myc-mGluR1aS936D
plus GIRK1, GIRK2 or TRPC1. Application of DHPG
evoked an inward current in HEK293 cells transfected
with myc-mGluR1a and either TRPC1 or GIRK1, 2. Mean
Neuron
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TRPC1-transfected cells was 36.7 ± 9.6 pA (mean ±
SEM, n = 7 cells), while in myc-mGluR1a/GIRK1, 2-trans-
fected cells, average amplitude of whole-cell current
was 24.2 ± 6.3 pA (n = 5 cells). In contrast, whole-cell
currents were markedly reduced or absent in cells trans-
fected with myc-mGluR1aS936D, with a mean amplitude
of 9.7 ± 6.8 pA in myc-mGluR1aS936D/TRPC1-trans-
fected cells (n = 5) and 1.4 ± 0.8 pA in myc-mGluR1-
aS936D/GIRK1, 2-transfected cells (n = 3). As illustrated
in Figure 4A, whole-cell response induced by wild-type
mGluR1a was significantly greater than that mediated by
truncated mGluR1a (p < 0.05, Student’s t test for myc-
mGluR1a versus myc-mGluR1aS936D in both TRPC1-
and GIRK1, 2-transfected cells).
As reported in previous studies, mGluR1 activation can
stimulate the PI3K-Akt signaling pathway through the
mGluRI-Homer-PIKE-PI3K signaling complex. Therefore,
we tested whether this signaling mechanism remained
functional after mGluR1a truncation. We first induced
Figure 3. C-Terminal Truncated mGluR1a Remains Func-
tional for Increasing Cytosolic Free Calcium
HEK293 cells were cotransfected with DsRED and myc-mGluR1a or
myc-mGluR1aS936D. DHPG was used to induce mGluR1a-mediated
calcium transient.
(A) Photos on the left show expression of DsRED, which labels trans-
fected cells; photos in the middle illustrate the fluorescent signal
obtained with the calcium indicator Oregon green 488 BAPTA-1 AM
before and after DHPG application; photos on the right are obtained
by subtracting ‘‘before DHPG’’ from ‘‘after DHPG,’’ thus representing
DHPG-induced calcium transients.
(B) Quantification of DHPG-induced calcium transients in myc-
mGluR1a- or myc-mGluR1aS936D-transfected cells; results are
means ± SEM of eight to ten experiments.NmGluR1a truncation by treating cortical neurons with
50 mM NMDA for 1 hr. Two hours after washing out
NMDA, neurons were incubated with DHPG (50 mM) for
10 min. Neurons were then lysed and levels of Akt phos-
phorylation were determined with western blots by calcu-
lating the ratio of phosphorylated Akt to total Akt. DHPG
induced a moderate increase in Akt phosphorylation
levels in neurons (p < 0.05, n = 6, Student’s t test for
cont1 versus DHPG1) (Figure 4B). Pretreatment with
NMDA reduced basal levels of phosphorylated Akt (p <
0.001, n = 6, Student’s t test for cont1 versus cont2).
Under this condition, DHPG failed to increase Akt phos-
phorylation levels (p = 0.27, n = 6, Student’s t test for
cont2 versus DHPG2). When neurons were pretreated
with 8 mM TAT-mGluR1 for 90 min to block mGluR1a trun-
cation, NMDA-induced reduction of Akt phosphorylation
was partially reversed (p < 0.05, n = 6, Student’s t test
for cont3 versus cont2). More importantly, DHPG-induced
increase of Akt phosphorylation was restored (p < 0.05,
n = 6, Student’s t test for cont3 versus DHPG3). Together,
the data indicated that the mGluR1a-PI3K-Akt signaling
pathway was disrupted by calpain-mediated mGluR1a
truncation and that preventing truncation with the TAT-
mGluR1 peptide restored this signaling mechanism.
C-Terminal Truncation Alters mGluR1a Targeting
in Cortical Neurons
Previous studies have shown that the C-terminal domain
of mGluR1a is crucial for its dendritic localization. There-
fore, it was interesting to determine whether mGluR1a
targeting was modified following calpain-mediated
truncation. Cortical neurons were transfected with myc-
mGluR1a. After 48 hr, neurons were treated with 50 mM
NMDA or vehicle for 1 hr. After 3 hr of washing out
NMDA, neurons were fixed and stained with antibodies
against the N-terminal myc epitope or the C terminus of
mGluR1a, respectively. Full-length mGluR1a was selec-
tively targeted to dendrites and almost excluded from
axons (Figure 5A). But in 34% of neurons treated with
NMDA (124 out of 367 neurons counted), myc immuno-
reactivity could be detected in axons, especially in the
proximal segment, whereas immunoreactivity for the C
terminus of mGluR1a was still restricted to dendrites
(Figure 5B). These results indicated that NMDA-induced
C-terminal truncation altered mGluR1a targeting.
To test whether NMDA-induced translocation of
mGluR1a from dendrites to axons was an active process
or passive diffusion after truncation, we transfected cortical
neurons with myc-mGluR1aS936D. Targeting of mGluR1-
aS936D 48 hr after transfection was dramatically different
from that of full-lengthmGluR1a (Figure 5C). In themajority
of transfected neurons (73%, 500 out of 681 neurons
counted), immunoreactivity for myc tag was strictly re-
stricted to cell bodies (Figure 5C, upper panel). The cell-
body restriction was the same when immunostaining was
performed 6 days after transfection, suggesting that it
was not the result of a delay in expression or delivery but
rather mediated by targeting signals. In a smaller fractioneuron 53, 399–412, February 1, 2007 ª2007 Elsevier Inc. 403
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mGluR1a was selectively targeted to axons (Figure 5C,
middle panel). There were also a few neurons (4.5%, 31
out of 681 neurons counted) where immunostaining ap-
peared in dendrites. However, in contrast to the even dis-
tribution of full-length mGluR1a in dendrites, truncated
mGluR1a formed large clusters (Figure 5C, bottom panel).
Distinct and Opposite Roles of Wild-Type
and Truncated mGluR1a in Excitotoxicity
Calpain-mediated mGluR1a truncation was induced
mainly by toxic concentrations of NMDA. The downstream
Figure 4. C-Terminal Truncation Alters mGluR1a Signaling
(A) Recordings of mGluR1-induced whole-cell currents in HEK293
cells. Representative current traces recorded fromHEK293 cells trans-
fected with either myc-mGluR1a (left panel) or myc-mGluR1aS936D
(right panel) and GIRK1, GIRK2 (top) or TRPC1 (bottom). DHPG
(100 mM in extracellular solution) was applied using a fast perfusion
system for the period indicated by the scale bars. Each trace is the
average of five continuous sweeps. Bar graphs represent means ±
SEM of DHPG-induced current amplitude recorded in cells transfected
with myc-mGluR1a or myc-mGluR1aS936D + GIRK1, GIRK2 (top right)
or TRPC1 (bottom right) (n = 3–7).
(B and C) Representative blots (B) and quantification (C) showing alter-
ations of mGluR1-Akt signaling by calpain-mediated truncation.
DHPG induced a moderate increase in Akt phosphorylation levels in
neurons (p < 0.05, cont1 versus DHPG1, n = 6). Pretreatment with
NMDA reduced levels of phosphorylated Akt (p < 0.001, cont1 versus
cont2, n = 6) and abolished DHPG effect (p = 0.27, cont2 versus
DHPG2, n = 6). Pretreatment with TAT-mGluR1 partially blocked
NMDA-induced reduction in levels of phosphorylated Akt (p < 0.05,
cont3 versus cont2, n = 6) and restored the effect of DHPG in activating
Akt (p < 0.05, cont3 versus DHPG3, n = 6).404 Neuron 53, 399–412, February 1, 2007 ª2007 Elsevier Inc.signaling pathways of mGluR1a, including intracellular
calcium release and activation of PI3K-Akt, are both
important for excitotoxicity. Therefore, we postulated
that NMDA-induced truncation would alter the role of
mGluR1a in neuronal toxicity. To test this possibility, we
first cotransfected neurons with green fluorescent protein
(GFP) and a control vector, wild-type mGluR1a, or trun-
cated mGluR1a. Two days later, neurons were treated
with 25 mM glutamate for 1 hr. Twelve hours after treat-
ment, neurons were stained with 0.5 mM ethidium homo-
dimer 1 (EthD-1) for 10 min to label nuclei of dead cells.
Numbers of GFP-expressing neurons and EthD-1-positive
GFP-expressing neurons on each 18 3 18 mm coverslip
were counted to calculate the percentage of dead cells.
Toxic effects of glutamate treatment could readily be ob-
served in most GFP-expressing neurons, which exhibited
significant neurite retraction (Figures 6A and 6B). In neu-
rons cotransfected with control vector, 35% (n = 9; an
average of 405 GFP-expressing neurons were counted
on each coverslip) of GFP-expressing neurons were pos-
itive for EthD-1 staining and therefore had died. In neurons
cotransfected with wild-type mGluR1a, only 15% of neu-
rons (n = 8; an average of 428 GFP-expressing neurons
were counted on each coverslip) were EthD-1 positive,
an effect that was statistically different from that in neu-
rons cotransfectedwith control vector (p < 0.01, Student’s
t test). In contrast, 59% of neurons cotransfected with
mGluR1aS936D (n = 9; an average of 439 GFP-expressing
neurons were counted on each coverslip) were EthD-1
positive, an effect significantly higher than observed in
neurons cotransfected with control vector (p < 0.05, Stu-
dent’s t test). The opposite effects of wild-type and trun-
cated mGluR1a indicated that wild-type and truncated
mGluR1a have distinct roles in excitotoxicity.
We then tested whether calpain-mediated truncation of
endogenous mGluR1a also alters its role in excitotoxicity.
We used NMDA to elicit mGluR1a truncation and evalu-
ated the role of mGluR1 in neuronal toxicity by applying
DHPG before and after truncation. Cortical neurons cul-
tured on 18 3 18 mm coverslips were divided into six
groups which received the following treatments: (1) con-
trol, vehicle; (2) NMDA, 100 mM NMDA for 1 hr; (3) DHPG
before NMDA, DHPG, 100 mM for 1 hr, followed by
100 mM NMDA for 1 hr; (4) DHPG after NMDA, NMDA,
100 mM for 1 hr, followed by 100 mM DHPG for 1 hr; (5)
DHPG + LY before NMDA, 100 mM DHPG was coapplied
with 100 mM LY367385 for 1 hr followed by 100 mM
NMDA for 1 hr; (6) DHPG + LY after NMDA, NMDA,
100 mM for 1 hr, followed by 100 mM DHPG coapplied
with 100 mM LY367385. One day after treatment, all neu-
rons were stained for 20 min with 0.5 mM EthD-1 to label
dead cells and 2 mM calcein AM to label live cells. After
washes, coverslips were mounted and one microscopy
photo was immediately taken of the center area of each
coverslip. EthD-1- and calcein AM-positive cells in each
photo were then counted. The percentage of dead cells
was calculated as the number of EthD-1-positive cells/
(number of EthD-1-positive cells + number of calcein
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mGluR1a Targeting
(A and B) Neurons were cotransfected with
DsRED and myc-mGluR1a. After 48 hr, neu-
rons were fixed and stained with anti-myc (A)
or anti-mGluR1a1142–1160 (B) and anti-DsRED
antibodies. Myc-mGluR1a (upper panel) was
not present in axons (arrowheads) under con-
trol conditions. After treatment with NMDA
(lower panel), myc-tag staining appeared in
the proximal segment of axons (A), while stain-
ing of the mGluR1a C terminus was still absent
in axons (B).
(C) Neurons were cotransfected with DsRED
and myc-mGluR1aS936D. Neurons were
stained with anti-myc and anti-DsRED anti-
bodies 48 hr later. In 73% of neurons, myc
immunoreactivity was restricted to cell bodies
(upper panel; arrowheads point to cell bodies);
in 20% of neurons, myc-mGluR1aS936D was
preferentially targeted to axons (middle panel;
arrowheads point to axons). In 5% of neu-
rons, myc-mGluR1aS936D was preferentially
targeted to dendrites and formed large clusters
(lower panel; arrowheads point to clusters in
dendrites).AM-positive cells) *100%. As shown in Figures 6C and 6D,
control had 8% cell death (n = 12). In NMDA, cell-death
rate increased to 37% (n = 12), which was significantly
higher than that in control (p < 0.001, Student’s t test), in-
dicating toxicity of NMDA; 29% cell death was found in
DHPG before NMDA (n = 9), which was significantly lower
than that ofNMDA (p < 0.001, Student’s t test), suggesting
a neuroprotective effect of DHPG under this condition.
This effect was blocked by coapplying LY367385
(DHPG + LY before NMDA, 35.1% cell death, n = 11;Np < 0.05 compared with DHPG before NMDA; p = 0.38
compared with NMDA, Student’s t test), indicating that it
was mediated by mGluR1. DHPG after NMDA had 54%
cell death (n = 12), which was significantly higher than
that ofNMDA (p < 0.001, Student’s t test), indicating a neu-
rotoxic effect of DHPG treatment under this condition.
This toxic effect was blocked by coapplying LY367385
(DHPG + LY after NMDA, 39.9% cell death, n = 9;
p < 0.001 compared with DHPG after NMDA; p = 0.27
compared with NMDA, Student’s t test). The oppositeeuron 53, 399–412, February 1, 2007 ª2007 Elsevier Inc. 405
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(A and B) Cortical neurons were cotransfected with GFP and vector DNA, myc-mGluR1a, or myc-mGluR1aS936D. Two days later, neurons were
treated with glutamate and after another 12 hr were stained with EthD-1 to label dead cells. Arrowheads in Figure 7A indicate EthD-1-positive
GFP-expressing neurons. *p < 0.05.
(C and D) Representative photos and bar graphs showing differential roles for endogenous mGluR1 in neuronal toxicity before and after NMDA-
induced truncation. Cortical neurons were treated as indicated (see Results for detailed description) and were stained with EthD-1 and calcein
AM (for live cells) 24 hr later. *p < 0.001.
(E and F) TAT-mGluR1 peptide protected neurons from NMDA toxicity. Neurons were treated with vehicle or TAT-mGluR1 at the indicated concen-
trations followed by NMDA. Neurons were stained with EthD-1 and calcein AM 24 hr later. *p < 0.001. Results are presented as means ± SEM,
Student’s t test.
(G) Schematic representation of the alterations in signaling and roles in excitotoxicity of mGluR1a resulting from NMDA receptor-induced calpain-
mediated truncation.406 Neuron 53, 399–412, February 1, 2007 ª2007 Elsevier Inc.
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(A) SD rats were injected with kainic acid. Hip-
pocampi were collected at the indicated times
after injection and homogenates were blotted
with anti-mGluR1a1142–1160 and anti-spectrin.
(B) FVB/N mice were injected with KA
and brains were fixed 18 hr after injection.
Brain sections were stained with anti-
mGluR1a1142–1160 and anti-GluR2/3.
(C) TAT-mGluR1 blocked truncation of
mGluR1a in vivo. FVB/N mice were injected
with vehicle or TAT-mGluR1 at the indicated
doses followed by KA injection. Hippocampi
were collected 12 hr after KA injection and
total homogenates were blotted with anti-
mGluR1a1142–1160 and anti-spectrin.
(D) TAT-mGluR1 did not affect KA-induced
seizures. FVB/N mice were injected (i.p.) with
vehicle or TAT-mGluR1 followed by KA.
Seizure activity was scored as described in
Experimental Procedures. Results are pre-
sented as means ± SEM, n = 10–14.
(E) Representative photos showing the neuro-
protective effect of TAT-mGluR1 in vivo. Mice
were first treated as described in (D). Seven
days later, mice were sacrificed and brains
were sectioned and processed for Nissl and
silver staining.effects of DHPG before and after NMDA-induced trunca-
tion thus demonstrate the distinct roles of full-length and
truncated endogenous mGluR1a.
Based on these data, we reasoned that blockade of
mGluR1a truncation might have neuroprotective effects.
To test this possibility, cortical neurons were incubated
with 2, 4, or 8 mM of TAT-mGluR1 peptide or vehicle for
90 min followed by 100 mM of NMDA for 1 hr. Neurons
were stained with EthD-1 and calcein AM to determine
the percentage of dead cells 24 hr after NMDA treatment.
NMDA treatment significantly increased the proportion of
dead cells (p < 0.001, n = 12–15, Student’s t test, NMDA
versus cont) (Figures 6D and 6F). Pretreatment with
TAT-mGluR1 peptide dose dependently reduced NMDA-
induced cell death (p < 0.001, n = 9–15, Student’s t test
for NMDA versus NMDA + TAT-mGluR1 8 mM, NMDA
versus NMDA + TAT-mGluR1 4 mM, and NMDA versus
NMDA + TAT-mGluR1 2 mM, respectively). The protective
effect of TAT-mGluR1 was significant at a concentration
as low as 2 mM, where the fusion peptide showed no sig-
nificant effect on spectrin degradation. These data sug-
gested that neuroprotection can be achieved by blocking
mGluR1a truncation.
Truncation of mGluR1a Contributes to Excitotoxicity
In Vivo
To test whether calpain-mediated truncation of mGluR1a
occurs with excitotoxicity in vivo, we used kainic acid-
induced seizure activity as a model, as neuronal damageresulting from seizures has been shown to be NMDA
receptor dependent and calpain activation has also
been well documented in this animal model (Siman and
Noszek, 1988). Two-month-old male SD rats received
systemic injection of kainic acid (KA) (i.p., 12 mg/kg). Hip-
pocampi were collected 3, 6, or 12 hr after injection, ho-
mogenized, and processed for immunoblots. As shown
in Figure 7A, the 38 kDa C-terminal fragment of mGluR1a
was detectable as early as 3 hr after KA injection. At 6 or 12
hr after injection, levels of full-length mGluR1awere signif-
icantly reduced. Similarly, the 145 kDa spectrin degra-
dation band was present after KA injection, indicating
that calpain was activated. A similar result was obtained
in FVB/N mice 12 hr after subcutaneous injection of KA
(30 mg/kg) (Figure 7C). Compared with that in cultured
neurons, immunoreactivity of the mGluR1a C-terminal
fragment after in vivo truncation was relatively weaker.
The weaker immunoreactivity of the C-terminal fragment
made it possible to determine the location of mGluR1a
truncation in vivo with immunohistochemistry. Immunore-
activity for mGluR1a in stratum radiatum of hippocampus,
especially in CA1, was significantly reduced following KA
injection (Figure 7B). Interestingly, mGluR1a immuno-
staining in stratum oriens was not reduced or even slightly
enhanced, suggesting that mGluR1a truncation might
take place mainly in pyramidal cells and not in interneu-
rons located in stratum oriens. GluR2/3 immunoreactivity
was not significantly changed except in theCA3 pyramidal
cell layer, where immunoreactivity largely disappeared.Neuron 53, 399–412, February 1, 2007 ª2007 Elsevier Inc. 407
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contributes to neuronal degeneration, we used the TAT-
mGluR1 fusion peptide to block truncation. FVB/N
mice were injected with different concentrations of TAT-
mGluR1 fusion peptide (i.p., 25, 50, or 100 mg/kg) or vehi-
cle 90 min before systemic KA injection (s.c., 30 mg/kg).
mGluR1a truncation was significantly reduced following
treatment with TAT-mGluR1 fusion peptide (50 and
100 mg/kg) (Figure 7C). As was observed in cultured
neurons, KA-mediated spectrin degradation was also re-
duced by peptide treatment. To eliminate the possibility
that blockade of calpain activation was due to an effect
of the peptide on seizure susceptibility, we analyzed the
effects of the fusion peptide on intensity and duration of
KA-induced seizure activity. FVB/N mice were injected
with 50 mg/kg TAT-mGluR1 peptide or vehicle followed
by KA injection 90 min later. We did not observe any be-
havioral abnormality in mice that received TAT-mGluR1
peptide. Peptide pretreatment did not significantly alter
KA-induced seizure (p > 0.05, n = 10–14, Student’s t test
for KA alone versus KA + TAT-mGluR1 for each hour,
respectively) (Figure 7D). We then tested whether block-
ade of mGluR1a truncation could protect hippocampal
neurons from KA-induced neurodegeneration. Because
KA-induced neuron degeneration is closely related to
seizure severity, only mice exhibiting stage 5 or higher
seizures (see Experimental Procedures for a detailed
description of the scale) were used for the cell toxicity ex-
periment. Mice were perfused and fixed 7 days after KA
injection. Brains were sectioned and processed for Nissl
and silver staining. Representative photos from KA alone
or peptide-pretreated (50 mg/kg) mice are shown in
Figure 7E. As previously reported in this mouse strain
(Schauwecker and Steward, 1997), KA induced severe
neurodegeneration in CA1 and CA3, as illustrated by the
reduction of Nissl staining and appearance of degener-
ated neurons in silver staining (degenerated neurons
were stained black). Pretreatment with the TAT-mGluR1
peptide significantly reduced KA-induced neurodegener-
ation, especially in CA1. Among the eight mice injected
with KA and vehicle, five exhibited severe neurodegener-
ation in CA1 and CA3, two mice exhibited moderate neu-
rodegeneration, and only one mouse appeared relatively
normal. In contrast, among the eight mice pretreated
with TAT-mGluR1 peptide, only two showed moderate
neurodegeneration, one showed a low level of neuro-
degeneration, while the remaining five appeared normal
(see Supplemental Data). Together, the data indicate
that blockade of mGluR1a truncation in vivo protects
neurons from KA-induced degeneration.
DISCUSSION
Altered Signaling and Targeting of mGluR1a
by Calpain-Mediated Truncation
Calpain is a family of calcium-activated cysteine prote-
ases.m-calpain andm-calpain are the twocalpain isoforms
ubiquitously distributed in mammalian cells. Calpain nor-408 Neuron 53, 399–412, February 1, 2007 ª2007 Elsevier Inc.mally induces limited cleavage of substrate proteins to
modify rather than abolish their functions (reviewed by
Goll et al., 2003). In the central nervous system, calpain
is important for neural development, synaptic plasticity,
and neural degeneration. Our laboratory previously dem-
onstrated calpain-mediated truncation of both AMPA (Bi
et al., 1996) andNMDA receptors (Bi et al., 1998). Thepres-
ent study demonstrates that calpain also truncates the C-
terminal domain of mGluR1a.
The mGluR1a signaling mechanism involves the Gq
family of heterotrimeric G proteins. Themajor signal trans-
duction mechanism for mGluR1 consists of activation of
phospholipase C (PLC), which hydrolyzes membrane
phosphoinositides and leads to IP3-mediated Ca
2+ re-
lease from intracellular stores (Masu et al., 1991). The
mGluR1a-G protein coupling involves mainly the second
intracellular loop of the receptor (Gomeza et al., 1996);
therefore, it is not surprising that mGluR1a remains func-
tional after calpain-mediated truncation, which removes
a long fragment from the intracellular C-terminal domain.
Besides interacting with G proteins, mGluR1a also directly
interacts via its large intracellular C-terminal domain with
several other proteins, including Homer family proteins
(Fagni et al., 2002), calmodulin and Siah1A (Ishikawa
et al., 1999), and membrane channels (Saugstad et al.,
1996; Kitano et al., 2003; Kim et al., 2003). The Homer
binding motif is located in the distal C terminus of
mGluR1a and downstream of the calpain cleavage site.
The binding of the receptor to Homer proteins is essential
for coupling mGluR1a with the PI3K-Akt system (Rong
et al., 2003). Homer proteins also serve as a bridge linking
mGluR1a in cell plasma membranes with IP3 receptors
in the endoplasmic reticulum membrane and facilitate
mGluR-dependent calcium release from intracellular
stores (Fagni et al., 2002). As expected, mGluR1-PI3K-
Akt signaling was disrupted by calpain-mediated trunca-
tion. The mGluR1a-induced calcium transient was also
moderately reduced. mGluR1a also gates some mem-
brane channels, such as TRPC1 (Kim et al., 2003) and
GIRK1, 2 (Saugstad et al., 1996), which transduce
mGluR1a-dependent excitatory postsynaptic current.
The detailed mechanism responsible for mGluR1a/mem-
brane channel interactions is largely unknown, and our
data indicated that the C-terminal sequence located
downstream of the calpain cleavage site is critical for
those interactions.
Using immunogold electromicroscopy, Lujan et al.
(1996) located mGluR1a to the perisynaptic area of post-
synaptic sites. Consistent with this finding, mGluR1a was
found to be selectively targeted to dendrites in cultured
neurons (Stowell and Craig, 1999). A detailed analysis of
mGluR1a targeting revealed two distinct targeting signals
in the C-terminal domain, RRK877–879 for axonal targeting
and another one located in more distal sequences. It has
been suggested that the axonal targeting signal is masked
by the proximal C terminus (residues 1012–1071) of
mGluR1a, resulting in selective delivery of mGluR1a to
dendrites (Francesconi and Duvoisin, 2002). In agreement
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tially targeted to axons in about 20% of neurons. But un-
like the 100% axonal targeting of the short mGluR1 splice
variant mGluR1b, mGluR1aS936D was strictly restricted
to cell bodies in the majority of neurons. This finding
suggests that, although mGluR1aS936D is very similar in
length to mGluR1b and mGluR1c, it might have different
targeting and signaling properties. What governs the
differential targeting of mGluR1aS936D (cell body or
axons) in individual neurons is unknown, but such target-
ing might be due to specific characteristics of neurons
(e.g., interneurons versus pyramidal neurons, or neurons
derived from different layers or different regions of the
cortex).
Potential Roles of NMDA Receptor/mGluR1
Interactions in Excitotoxicity
NMDA receptors andmGluR1 are colocalized on the post-
synaptic membrane and coactivated by glutamate release
from presynaptic sites. Functional interactions between
these two types of receptors have long been noted (Lan
et al., 2001). Physical interactions between the two recep-
tors have also been proposed. It was suggested that
mGluR1 could be linked to NMDA receptors through the
Homer-Shank-PSD95 complex (Tu et al., 1999) or by
Ephrin (Calo et al., 2005). These physical interactions
would keep mGluR1 close to NMDA receptor channels
and target it for cleavage by locally activated calpain.
Interactions between NMDA and mGluR1 receptors in
excitotoxicity appear complicated. Activation of mGluR1
was reported to attenuate NMDA-induced neurotoxicity
in cortical neuronal cultures (Koh et al., 1991) and in orga-
notypic hippocampal slice cultures (Baskys et al., 2005).
Similarly, pretreatment with mGluRI agonists reduced
the excitotoxic effects induced in the retina by intraocular
NMDA injection (Siliprandi et al., 1992). However, many
studies have indicated that mGluR1 activation exacer-
bates NMDA receptor-mediated neurotoxicity (Calo
et al., 2005; Bruno et al., 1995). Interestingly, activation
of mGluR1 before NMDA application tends to be neuro-
protective (Blaabjerg et al., 2003), whereas activation of
mGluR1 after NMDA application tends to enhance
NMDA toxicity (Bruno et al., 1995). Similarly, the protective
effects of mGluRI agonists in ischemia are time depen-
dent: they are neuroprotective only when administered
before the onset of ischemia (Schroder et al., 1999).
Our findings regarding NMDA-induced mGluR1a trun-
cation provide a possible explanation for these phenom-
ena: before NMDA application or onset of ischemia,
mGluR1a receptors are coupled to PI3K-Akt signaling
and their activation is neuroprotective. AlthoughmGluR1a
activation leads to calcium release from internal stores,
the extent of calcium release might be too low and
transient to produce significant toxic effects. Following
NMDA application or onset of ischemia, NMDA receptor
activation induces calpain-mediated truncation of
mGluR1a. As a result, the neuroprotective effect of the
mGluR1a-PI3K-Akt signaling cascade would be disrup-ted. In addition, mGluR1a-dependent calcium release
from intracellular stores would further contribute to cal-
cium overload due to calcium influx through NMDA recep-
tors and thus enhance neurotoxicity. Finally, because
mGluR1 also exhibits presynaptic localization and func-
tion (Herrero et al., 1998; Moroni et al., 1998), truncation-
mediated mGluR1a translocation to axons might further
enhance glutamate release, thereby exacerbating excito-
toxicity. Together, NMDA receptor activation followed by
calpain-mediated truncation of mGluR1a constitutes
a positive feedback loop for excitotoxicity.
Accumulating evidence suggests that calpain also plays
a critical role in excitotoxicity. Overactivation of NMDA re-
ceptors leads to calpain activation, and calpain blockade
protects neurons from excitotoxicity (Higuchi et al., 2005).
By cleaving different substrates, calpain triggers multiple
neurotoxicity mechanisms. First, by partial truncation of
NMDA receptors (Simpkins et al., 2003) and the Na+/Ca
exchanger (Bano et al., 2005), calpain enhances calcium
overload. Second, through degradation of intracellular
antiapoptotic proteins, such as NF-kB (Scholzke et al.,
2003), calpain promotes cell-death signaling. Third, by de-
grading cytoskeleton proteins such as spectrin, calpain
disrupts cell structure. In the current study, we show
that calpain-mediated mGluR1a truncation plays a critical
role in excitotoxicity by both disrupting neuroprotective
signaling and enhancing neurotoxic signaling. In the future
it will be interesting to test the involvement of this positive
feedback loop, namely NMDA receptor/calpain activa-
tion/mGluR1a truncation in other models of neurodegen-
eration where excitotoxicity has been implicated, such
as ischemia, Parkinson’s disease, and Alzheimer’s dis-
ease. Moreover, further optimization of the TAT-mGluR1
peptide might provide a very useful tool not only to test
this mechanism in these diseases but also to develop
new therapeutic treatments.
EXPERIMENTAL PROCEDURES
Materials
Monoclonal anti-mGluR1a1142–1160 antibody (610965) was obtained
from BD Pharmingen (San Diego, CA, USA), anti-myc (ab32) was
from Abcam (Cambridge, MA, USA), anti-mGluR5 (06-451) was from
Upstate (Charlottesville, VA, USA), anti-VGluT1 (135 302) was from
Synaptic Systems (Goettingen, Germany), anti-spectrin (1622) and
anti-GluR2/3 (1506) were from Chemicon (Temecula, CA, USA), and
anti-phospho-Akt (S473) (AF887) and total Akt (MAB2055) were from
R&DSystems (Minneapolis, MN, USA). Human m-calpain was obtained
from Sigma (C6108; St. Louis, MO, USA), calpain inhibitor III (208722)
and cpm-VAD-CHO (218830) were from Calbiochem (San Diego, CA,
USA), APV, CNQX, DHPG, LY367385, and MPEP were from Tocris (El-
lisville, MO, USA), and NVP-AAM077was a gift fromDr. Yves P. Auber-
son. TAT peptide was obtained from Anaspec (San Jose, CA, USA).
TAT-mGluR1 peptide was synthesized by USC/Norris Comprehensive
Cancer Center Core Facilities. The myc-mGluR1a construct was ob-
tained from Dr. Anna Francesconi. GST-mGluR1a fusion proteins
were made by subcloning mGluR1a sequences 812–943 or 889–
1058 into PEGX 4T-1. mGluR1aS936D was made by introducing
a stop codon right after Ser936 of myc-mGluR1a. The constructs
were verified by sequencing.Neuron 53, 399–412, February 1, 2007 ª2007 Elsevier Inc. 409
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Neurons from E18 rat cortex were dissociated and plated in neuro-
basal medium supplemented with B27, 0.5 mM glutamine, and
12.5 mM glutamate in six-well plates at 105 cells/well for immuno-
staining and in 60 mm dishes at 13 106 cells/dish for immunoblotting.
Neurons were switched to maintenance medium (neurobasal medium
supplemented with B27 and 0.5 mM glutamine) the next day and fed
twice per week until ready for experiments at 14–18 DIV. Neurons
were transfected with a modified calcium phosphate precipitation
method (Jiang et al., 2004). HEK293 cells were transfected with
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA).
SDS-PAGE and Immunoblotting
Cultured cells or brain tissues were homogenized in boiling lysis buffer
(1% SDS, 10 mM Tris, 0.2 mM sodium ortho-vanadate [pH 7.4]). The
lysate was denatured at 95C for 5–10 min, sonicated, and centrifuged
at 14,000 rpm for 30 min. Supernatants containing equal amounts of
total proteins were processed for SDS-PAGE and immunoblotted
with standard chemiluminescence protocols. Blots were digitized
and quantified with NIH image software. All band intensities were nor-
malized to that of control samples. For immunoprecipitation, cells were
lysed with modified radioimmunoprecipitation buffer and lysates were
incubated with anti-myc or anti-mGluR1a1142–1160 antibodies. Proteins
were pulled down with protein A agarose. Silver staining of SDS gels
was conducted with the European Molecular Biology Laboratory silver
staining protocol.
Immunocytochemistry, Immunohistochemistry,
and Silver Staining
For immunocytochemistry, neurons were fixed with 4% formaldehyde
in PBS (room temperature, 10 min) and permeabilized with 1% Triton
X-100 for 5 min. After blocking with 5% goat serum (60 min), neurons
were incubated with primary antibodies dissolved in 0.5% goat serum
in PBS for 1 hr. Neurons were then incubated with a corresponding
fluorescence-tagged secondary antibody for 30 min. For immuno-
histochemistry, mice were deeply anesthetized with ketamine and
xylazine and intracardially perfused with 20 ml chilled PBS (pH 7.4)
followed by 100 ml 4% formaldehyde. Brains were removed and post-
fixed for 2 hr at room temperature. After incubating in PBS with 30%
sucrose until sinking, brains were cut into 30 mm thick sections on
a cryostat. Free-floating brain sections were immunostained with a
VECTASTAIN ABC (standard) kit from Vector Laboratories (Burlin-
game, CA, USA). Brain-section silver staining was conducted with
FD NeuroSilver kit I from FD NeuroTechnologies (Ellicott City, MD,
USA) with the manufacturer-provided protocol.
Electrophysiological Recordings
HEK293 cells plated on poly-D-lysine-coated coverslips were trans-
fected with mGluR1a (either wild-type or truncated form) + TRPC1 +
red fluorescent protein (DsRED), or DsRED alone, using lipofectamine
(Lipofectamine 2000; Invitrogen). For each well of a 24-well plate,
0.5 mg lipofectamine and cDNAs (0.4 mg mGluR1a + 0.4 mg TRPC1 +
0.1 mg DsRED; DsRED alone, 0.1 mg) were used for transfection. Elec-
trophysiological recording was conducted 48 hr after transfection. In
some experiments, TRPC1 was replaced with G protein-coupled in-
wardly rectifying potassium channel cDNAs (GIRK1 and GIRK2,
0.4 mg each). HEK293 cells on coverslips were transferred to a record-
ing chamber continuously perfused with extracellular solution (ECS)
(pH 7.4) containing 140 mM NaCl, 5.4 mM KCl, 1 mM MgCl2,
1.3 mM CaCl2, 25 mM HEPES, and 33 mM glucose. Transfected cells
were identified from their DsRED signal under a fluorescence upright
microscope. Patch pipettes were pulled from borosilicate glass capil-
laries (Sutter Instrument Company, Novato, CA, USA) and filled with an
intracellular solution (pH 7.2) (300–310 mOsm) composed of 115 mM
Cs gluconate, 17.5 mM CsCl, 10 mM HEPES, 2 mM MgCl2, 10 mM
EGTA, 4 mM ATP, and 0.1 mM GTP. For GIRK current recordings,
the Cs in the intracellular solution was replaced with K+. Recordings410 Neuron 53, 399–412, February 1, 2007 ª2007 Elsevier Inc.of whole-cell currents were obtained following application of DHPG
(100 mM) using a fast perfusion system. An Axopatch 200B amplifier
(Axon Instruments, Union City, CA, USA) was used for recording. Ac-
cess resistance was monitored throughout each experiment. Record-
ings with a series resistance variation of more than 10%were rejected.
No electronic compensation for series resistancewas used.Whole-cell
current recordings were performed in voltage-clamp mode and the
membrane potential was maintained at 60 mV. Recorded currents
were blocked by the mGluR1 antagonist LY367345 (50 mM; Sigma)
(data not shown). Recordings were low-pass filtered at 2 kHz, sampled
at 10 kHz, and stored on a PC using Clampex 8.2 (Axon).
Calcium Imaging
HEK293 cells plated on poly-D-lysine-coated 16 mm coverslips were
transfected with mGluR1a (either wild-type or truncated form) +
DsRED. Two days after transfection, cells were incubated with a cal-
cium reporter Oregon green 488 BAPTA-1 AM (0.63% in ECS) for
30 min. After washes with ECS, intracellular calcium concentration
changes in Oregon green-loaded cells were monitored with a cool
CCD camera mounted on a microscope under a 633 objective with
the help of Openlab 3.7.5 software (Improvision, Coventry, UK) running
on a PowerMac computer. Although all HEK cells were loaded with
Oregon green, only 10%–20% of them were mGluR1 transfected so
that nontransfected HEK cells in the same visual field could be used
as controls. To induce mGluR1-dependent intracellular calcium re-
lease, cells were perfused with an extracellular solution containing
100 mM DHPG for 15 s. Images were acquired continuously before
and after DHPG application at 5 Hz for 30 s and analyzed offline using
Image J software (National Institutes of Health).
Cell Toxicity Assay
Cell live/dead condition of cultured neurons was assessed with the
LIVE/DEAD Viability/Cytotoxicity kit (L-3224; Invitrogen). In this kit,
EthD-1 (ethidium homodimer 1, red fluorescent when binding to DNA)
is used to stain the nucleus of dead cells with disrupted cell membrane
integrity; calcein AM (green fluorescent once it is converted by the es-
terase of live cells) is used to stain live cells. Cultured cortical neurons
were incubated with 0.5 mM EthD-1 and/or 2 mM calcein AM (diluted
with neurobasal culturemedium) for 10–20min andwashedwith neuro-
basal medium twice before observation under the microscope.
Behavioral Assessment of KA-Induced Seizure Activity
Seizure activity was assessed with methods described by Holcik et al.
(2000) with some modifications. Mice were assigned a score every
5min after KA injection according to a seven-stage scale: 0 represents
normal behavior; 1, immobility; 2, rigid posture; 3, repetitive scratch-
ing, circling, or head bobbing; 4, forelimb clonus, rearing, and falling;
5, repeated episodes of level 4 behaviors; 6, severe tonic-clonic be-
havior; and 7, death. The 12 scores obtained each hour following KA
injection were summed to generate the seizure score for that hour.
All animal experiments were conducted in accordance with NIH guide-
lines and protocols approved by the Institutional Animal Care and Use
Committee with care to minimize distress to the animals.
Supplemental Data
Supplemental Data include the effects of mGluR1a point mutations on
calpain-mediated truncation and of TAT-mGluR1 peptide on calpain-
mediated truncation of mGluR1a in brain membrane fractions and on
kainic acid-induced neurodegeneration, and can be found with this
article online at http://www.neuron.org/cgi/content/full/53/3/399/
DC1/.
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